Overview
Empagliflozin is an oral sodium-glucose co-transporter 2 (SGLT2) inhibitor. It is prescribed for adults with type 2 diabetes to improve glycaemic control and has notable cardiovascular and renal protective benefits, including reducing the risk of cardiovascular death and hospital admissions for heart failure.

Mechanism of Action
It inhibits SGLT2, the primary transporter responsible for glucose reabsorption in the proximal renal tubules. By blocking this transporter, empagliflozin reduces renal reabsorption of filtered glucose and lowers the renal threshold for glucose, thereby increasing urinary glucose excretion and lowering blood glucose levels independently of insulin.

Dosage and Administration
The recommended starting dose is 10 mg once daily in the morning, taken with or without food. In patients tolerating the drug well, the dose may be increased to 25 mg daily for additional glycaemic control. Adequate renal function is required for it to be effective.

Side Effects
Common side effects include fungal infections of the genitals (such as thrush and balanitis), urinary tract infections, and increased urination. It can cause a reduction in the amount of fluid in the blood, leading to low blood pressure. A rare but serious risk is ketoacidosis that occurs when blood sugar levels are normal.

Contraindications
It is contraindicated in patients with a history of serious hypersensitivity to empagliflozin and in patients on dialysis. It is not indicated for type 1 diabetes.

Pregnancy and Lactation
Empagliflozin is not recommended during the second and third trimesters of pregnancy due to potential adverse effects on fetal renal development. It is also not recommended during breastfeeding.